Cipher Pharmaceuticals

218 articles with Cipher Pharmaceuticals

• Notice of Cipher Pharmaceuticals Fiscal 2007 Second Quarter Conference Call

  7/13/2007

• Cipher Pharmaceuticals Enters into U.S. Licensing and Distribution Agreement for Lipofen

  7/10/2007

• Cipher Pharmaceuticals Receives Approvable Letter from FDA for CIP-ISOTRETINOIN; FDA Seeks More Clinical Data

  4/27/2007

• Cipher Pharmaceuticals Annual and Special Meeting of Shareholders

  4/13/2007

• Cipher Pharmaceuticals Reports Fiscal 2006 Year-end Results

  3/7/2007

• Notice of Cipher Pharmaceuticals Conference Call

  2/27/2007

• Cipher Pharmaceuticals's Response To Approvable Letter For CIP-ISOTRETINOIN Accepted For Review By FDA

  1/17/2007

• Notice Of Cipher Pharmaceuticals Conference Call

  10/26/2006

• Cipher Pharmaceuticals Tramadol Fails Phase 3 Trial; Stock Tumbles 25%

  9/11/2006

• Cipher Pharmaceuticals Appoints New Chief Executive Officer

  8/8/2006

• Cipher Pharmaceuticals Reports 2006 Second Quarter Results

  8/4/2006

• Notice Of Cipher Pharmaceuticals Conference Call

  7/26/2006

• Cipher Pharmaceuticals Submits NDA For Once-Daily TRAMADOL Formulation

  6/29/2006

• Cipher Pharmaceuticals Appoints Vice President Of Scientific Affairs

  6/23/2006

• Cipher Pharmaceuticals Provides Update On Regulatory Path For CIP-TRAMADOL ER

  6/15/2006

• Cipher Pharmaceuticals Receives Health Canada Approval Of CIP-Fenofibrate

  2/21/2006

• Cipher Pharmaceuticals Provides CIP-Tramadol ER Update

  1/27/2006

• FDA Approves Cipher Pharmaceuticals Cholesterol Treatment

  1/13/2006